tabalumab   

GtoPdb Ligand ID: 8000

Synonyms: LY 2127399 | LY2127399
Compound class: Antibody
Comment: Tabalumab is a monoclonal antibody directed against B-cell activating factor (BAFF, TNFSF13B). It was being developed as a treatment for autoimmune diseases [1] and B cell malignancies [2].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence BLAST search using the heavy chain variable region of tabalumab provides 100% match to a sequence claimed in patent US7317089 [3], and to the antibody with designation 4A5-3.1.1-B4.
References
1. Chugh PK. (2012)
Lupus: novel therapies in clinical development.
Eur. J. Intern. Med., 23 (3): 212-8. [PMID:22385876]
2. Iida S, Ogiya D, Abe Y, Taniwaki M, Asou H, Maeda K, Uenaka K, Nagaoka S, Ishiki T, Conti I et al.. (2016)
Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma.
Cancer Sci., 107 (9): 1281-9. [PMID:27350068]
3. Kikly KK. (2008)
Immunmoglobulin specific to tumor necrosis factor (ligand) superfamily, member 13b (tnfsf13b) protein for use in treatment and prevention of autoimmune, inflammatory, respiratory system, skin , blood and cell proliferative disorders.
Patent number: US7317089. Assignee: Eli Lilly And Company. Priority date: 16/08/2001. Publication date: 08/01/2008.
4. Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, Plebani A, Lougaris V, Quinti I, Thon V et al.. (2012)
Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors.
J. Immunol., 188 (1): 497-503. [PMID:22124120]
5. Tanaka Y, Takeuchi T, Akashi N, Takita Y, Kovacs B, Kariyasu S. (2017)
Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study.
Mod Rheumatol, 27 (2): 284-291. [PMID:27471815]